A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk

Acta Dermato-Venereologica

Volumn 81, Issue 1, 2001, Pages 14-17

  Cunliffe, William J ^a   Glass, Daniel ^a   Goode, Karen ^b   Stables, Graham I ^a   Boorman, Graham C ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b Stiefel International R and D   (United Kingdom)

Author keywords

Plasma retinoid levels; Topical isotretinoin

Indexed keywords

BENZOYL PEROXIDE; ISOTRETINOIN; ISOTREXOL; RETINOIC ACID; SOLUGEL; SUNSCREEN;

ACNE; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; SKIN PROTECTION; TANDEM MASS SPECTROMETRY;

EID: 0035006332     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155501750208119     Document Type: Article

References (13)

1. Chalker DK, Lesher JL Jr, Smith JG Jr, et al. Efficacy of topical isotretinoin 0.05% gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17: 251-254.
2. Langner A, Boorman G, Stapor V, Wolska H, Fraczykowska M. Isotretinoin cream 0.05% and 0.1% in the treatment of acne vulgaris. J Dermatol Treat 1994; 5: 177-180.
3. Mills OH, Kligman AM. Therapeutic options in the management of acne and its variants. Semin Dermatol 1982; 1: 233-237.
4. Plewig G, Ruhfus A, Klovekorn W. Sebum suppression after topical application of retinoids (arotinoid and isotretinoin). J Invest Dermatol 1983; 80: 357.
5. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical applications of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991; 24: 425-428.
6. Durand A, Bun H, Vienne J-L. Comparative, multicentre, open trial of the plasma levels of tretinoin, 4-oxo-tretinoin, isotretinoin and 4-oxo-isotretinoin after repeated cutaneous application of tretinoin gel 0.05% or isotretinoin gel 0.05%. Stiefel Report No. CO259/E. Location: Stiefel, 1990.
7. Stables G, Glass D, Boorman GC, Seukeran DC, Cunliffe WJ. Topical isotreinoin alone or in combination with topical erythromycin: no clinical absorption even after "maximised" use. Br J Dermatol 1996; 135(Suppl. 47): 28.
8. Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: influence of vehicle, light exposure and dose. J Invest Dermatol 1988; 1: 56-61.
9. Lehman PA, Malany AM. Evidence for percutaneous absorption of isotretinoin from the photo-isomerization of topical tretinoin. J Invest Dermatol 1989; 93: 595-599.
10. Noctor TAG, Hemsley MJ, Sharp E. Compounds posing an endogenous blank problem: retinoids. In: Reid E, Hill HM, Wilson ID, eds. Methodological surveys in bioanalysis of drugs, Vol. 24. London: The Royal Society of Chemistry, 1996: 151.
11. Clark SM, Cunliffe WJ, Boorman GC. A double-blind, parallel group, clinical evaluation of the efficacy and safety of isotretinoin (0.05%) gel, erythromycin (2%) gel, a gel containing isotretinoin (0.05%) and erythromycin (2%) and a gel base (placebo) in the topical treatment of acne vulgaris. Br J Dermatol 1996; 135 (Suppl. 47): 28-29.
12. Eckhoff C, Nau H. Identification and quantification of all-trans- and 13-cis-retinoic acid and 13-cis-4-oxoretinoic acid in human plasma. J Lipid Res 1990; 31: 1445-1454.
13. Buss NE, Tembe BD, Prendergast AG, Renwick AG, George CF. The teratogenic metabolites of vitamin A in women following supplements and liver. Human Exp Toxicol 1994; 13: 33-43.